

Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: May 15, 1995.

Diane D. Porter,

Acting Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC).

References

1. U.S. General Accounting Office, (1991). Child Labor: Characteristics of Working Children. Publication No. GAO/HRD-91-83BR. Washington, D.C.: Author.
2. Castillo KN, Landen DD, Layne LA, (1994). Occupational injury deaths of 16- and 17-year olds in the United States. *American Journal of Public Health* 19: 739-45.
3. Layne LA, Castillo DN, Stout N, Cutlip P, (1994). Adolescent occupational injuries requiring hospital emergency department data. *American Journal of Public Health*. 84-4: 657-660.
4. Centers for Disease Control, (1983) Surveillance of occupational injuries treated in hospital emergency rooms—United States, 1982. *Morbidity and Mortality Weekly Report* 32 (2SS): 713-716.
5. Knight EB, Castillo DN, Layne LA (in press). A detailed analysis of work-related injury among youth treated in emergency departments. *American Journal of Industrial Medicine*.
6. Bush D, Baker, R (1994). *Young Workers at Risk: Health and Safety Education and the Schools*. Berkeley, CA: Labor Occupational Health Program.
7. Borman KM, Izzo MV, Penn E, Reisman J, (1984). *The Adolescent Worker*. Columbus, OH: National Center for Research in Vocational Education.
8. Jackson C, Fortmann SP, Flora JA, Melton RJ, Snider JP, Littlefield D, (1994) The capacity-building approach to intervention maintenance implemented by the Stanford Five-City Project. *Health Education Research*, 9, 3:385-396.
9. Rogers EM, Shoemaker F (1973). *Communication of Innovations*. New York: Free Press.

[FR Doc. 95-12325 Filed 5-18-95; 8:45 am]

BILLING CODE 4163-19-P

Hospital Infection Control Practices Advisory Committee: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Hospital Infection Control Practices Advisory Committee.

Times and Dates: 8:30 a.m.-5 p.m., June 12, 1995. 8:30 a.m.-4 p.m., June 13, 1995.

Place: CDC, Auditorium A, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The committee is charged with providing advice and guidance to the

Secretary, the Assistant Secretary for Health, the Director, CDC, and the Director, National Center for Infectious Diseases (NCID), regarding the practice of hospital infection control and strategies for surveillance, prevention, and control of nosocomial infections in U.S. hospitals and updating of guidelines and other policy statements regarding prevention of nosocomial infections.

Matters to be Discussed: The agenda will include review and discussion of public comments regarding the draft Guideline for Isolation Precautions in Hospitals, review of the status of the draft Guideline for the Prevention of Nosocomial Intravascular Device-Related Infections, review of the status of the proposed first draft of the Guideline for Infection Control in Hospital Personnel, and an update on CDC activities of interest to the committee. Agenda items are subject to change as priorities dictate.

Contract Person for More Information: Marsha A. Jones, Associate Director for Management, Hospital Infections Programs, NCID, CDC, 1600 Clifton Road, NE, Mailstop A-07, Atlanta, Georgia 30333, telephone 404/639-6402.

Dated: May 12, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 94-12326 Filed 5-18-95; 8:45 am]

BILLING CODE 4163-18-M

National Committee on Vital and Health Statistics: Meeting

Pursuant to Pub. L. 92-463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following committee meeting.

Name: National Committee on Vital and Health Statistics (NCVHS).

Times and Dates: 1 p.m.-5 p.m., June 14, 1995. 9 a.m.-5 p.m., June 15, 1995. 9 a.m.-3 p.m., June 16, 1995.

Place: Room 703A, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open.

Purpose: The purpose of this meeting is for the committee to consider reports from each NCVHS subcommittee; to receive reports from offices of the Department of Health and Human Services; to receive a report from the Center for Health Policy Studies on a working compendium of core health data sets currently in use or proposed for use for person level and event level in the United States; to discuss the Unified Medical Language System developed by the National Library of Medicine; and to address new business as appropriate.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road,

Hyattsville, Maryland 20782, telephone 301/436-7050.

Dated: May 12, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 94-12327 Filed 5-18-94; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 94F-0431]

Asahi Chemical Industry Co., Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Asahi Chemical Industry Co., Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of two grades of dimethylpolysiloxane with viscosities of 100 centistokes and 50 centistokes, intended for use as release agents in the manufacture of thermoplastic elastomers.

DATES: Written comments on the petitioner's environmental assessment by June 19, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3091.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 3B4396) has been filed by Asahi Chemical Industry Co., Ltd., Hibiya-Mitsui Bldg., 1-2, Yuraku-cho 1-Chome, Chiyoda-ku, Tokyo, T100, Japan. The petition proposes to amend the food additive regulations to provide for the safe use of two grades of dimethylpolysiloxane with viscosities of 100 centistokes and 50 centistokes, intended for use as release agents in the manufacture of thermoplastic elastomers.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental

assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before June 19, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and

this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: May 9, 1995.

George H. Pauli,
Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95-12296 Filed 5-18-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95N-0127]

Roussel Corp., et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 16 abbreviated new drug applications (ANDA's). The holders of the ANDA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: June 19, 1995.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD-360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1038.

SUPPLEMENTARY INFORMATION: The holders of the ANDA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

ANDA no.	Drug	Applicant
62-830	Sterile Cefazolin Sodium, U.S.P. (bulk)	Roussel Corp., 95 Chestnut Ridge Rd., P.O. Box 30, Montvale, NJ 07645.
70-662	Diazepam Injection, U.S.P., 5 milligrams (mg)/milliliter (mL) ..	Fujisawa Pharmaceutical Co., Parkway North Center, Three Parkway North, Deerfield, IL 60015-2548.
80-517	Prednisolone Sodium Phosphate Injection, U.S.P., 20 mg/mL	Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043-4705.
80-702	Vitamin A Palmitate Capsules, EQ 50,000 Units Base	Banner Pharmacaps, Inc., 1111 Jefferson Ave., Elizabeth, NJ 07207.
83-531	Dimenhydrinate Injection, U.S.P., 50 mg/mL	Steris Laboratories, Inc.
83-593	Chlorpheniramine Maleate Injection, U.S.P., 10 mg/mL	Do.
83-948	Vitamin A Palmitate Capsules, EQ 50,000 Units Base	Banner Pharmacaps, Inc.
83-973	Vitamin A Capsules, 50,000 U.S.P. Units	Do.
85-591	Chlorpromazine Hydrochloride Injection, U.S.P., 25 mg/mL ...	Steris Laboratories, Inc.
86-419	Testosterone Injection, U.S.P., 50 mg/mL	Do.
86-420	Testosterone Injection, U.S.P., 25 mg/mL	Do.
86-468	Procainamide Hydrochloride Extended-release Tablets, U.S.P., 250 mg.	Parke-Davis, Division of Warner-Lambert Co., 2800 Plymouth Rd., Ann Arbor, MI 48105.
86-844	Acetic Acid Otic Solution with Hydrocortisone, 2%/1%	Procter & Gamble Pharmaceuticals, 11370 Reed Hartman Hwy. Cincinnati, OH 45241-2422.
86-845	Acetic Acid Otic Solution, U.S.P., 2%	Do.
87-274	Hydroxyzine Hydrochloride Injection, U.S.P., 25 mg/mL and 50 mg/mL.	Steris Laboratories, Inc.
88-642	Diethylpropion Hydrochloride Tablets, U.S.P., 25 mg	Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the ANDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective June 19, 1995.

Dated: April 18, 1995.

Murray M. Lumpkin,
Deputy Director, Center for Drug Evaluation and Research.

[FR Doc. 95-12295 Filed 5-18-95; 8:45 am]

BILLING CODE 4160-01-F

Public Health Service

Agency Forms Undergoing Paperwork Reduction Act Review

Each Friday the Public Health Service (PHS) publishes a list of information collection requests under review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the PHS Reports Clearance Office on (202) 690-7100.

The following requests have been submitted for review since the list was last published on May 12.

1. Studies of Adverse Reproductive Outcomes in Female Occupational Groups—New—The reproductive health of a group of female workers exposed to a particular environmental chemical agent will be compared to the reproductive health of a group of working women with no occupational exposure to known or suspected reproductive toxicants. Respondents: Individuals or households; Business or other for-profit. Send comments to Shannah Koss, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503.